Logo Image
Publication|Videos|May 13, 2024

At DCAT With Piramal Pharma Solutions

Peter DeYoung, CEO, Piramal Pharma Solutions, talks about recent company achievements and key offerings, as well as current industry trends.

At a recent Drug, Chemical & Associated Technologies (DCAT) conference, Pharmaceutical Technology spoke with Peter DeYoung, CEO, Piramal Pharma Solutions, to learn more about the company's offerings. Watch to learn more about:

  • Piramal's key service offerings and integrated solutions in the areas of oncology and ADCs.
  • The current operating environment for CDMOs and industry trends.
  • Piramal's strategy to expand its territorial footprint in the US beyond its existing facilities.

Related to this article

View more
CPHI Milan 2026: Nitrosamine Risk Mitigation, Part 2
CPHI Milan 2026: Nitrosamine Risk Mitigation, Part 2
Mitigating nitrosamine risk requires assessing each product individually, says Bram Baert, Global Head of Regulatory Affairs at Capsugel, and Sandrine Picco, Senior Analytical Specialist on Capsugel's Innovaform Accelerator Team, in this interview with PharmTech.
Read more
Trophy and confetti on light background, top view with space for text. Victory concept | Image Credit: ©New Africa -stock.adobe.com
Winners of the 2026 CPHI Pharma Awards Announced
The winners of the CPHI Pharma Awards 2026 include a neurodegeneration platform, a track-and-trace packaging innovation, a enzymatic mRNA manufacturing technology, and a cell-free enzymatic biomanufacturing platform.
Read more
CPHI Milan 2026: Nitrosamine Risk Mitigation, Part 1
CPHI Milan 2026: Nitrosamine Risk Mitigation, Part 1
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
Read more